John Rossi
Company: Cero Therapeutics Inc.
Job title: Senior Vice President, Head of Translational Medicine
Seminars:
Panel Discussion: Leveraging Innate & Adaptive Systems to Open the Therapeutic Window with Novel, Rational Combinations 9:30 am
Which approach holds more potential: doubling down on T-Cell activity through combination therapy with PD-1/PD-L1 (for example), or harnessing alternative cell types such as innate immune cell engagers and gamma delta T-Cells? Evaluate the key risks and opportunities presented by each of these approaches Consider the limitations of these areas Discuss the ideal sequencing of…Read more
day: Day Two